Trial reportAlimentary pharmacology & therapeutics2006
Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
Trial report in Alimentary pharmacology & therapeutics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies.Journal of clinical medicine · 2026Review
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Modern Management of Gastric Neuroendocrine Neoplasms.Current treatment options in oncology · 2024Review
- Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin BInternational journal of molecular sciences · 2024Article
- Article
- Article
- Radiological Features of Zollinger-Ellison Syndrome: A Report of Two Cases.The Indian journal of radiology & imaging · 2022Article
- Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.World journal of gastroenterology · 2021Review
- Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.Endocrine reviews · 2020Review
- Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?The American journal of gastroenterology · 2018Review
- Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature.Case reports in gastrointestinal medicine · 2018Article
- Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Digestive diseases and sciences · 2017Review
- Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea.Gastroenterology research · 2016Article
- The Indications, Applications, and Risks of Proton Pump Inhibitors.Deutsches Arzteblatt international · 2016Review
- Gastric Hypersecretory States: Investigation and Management.Current treatment options in gastroenterology · 2015Article
- Pharmacotherapy of Zollinger-Ellison syndrome.Expert opinion on pharmacotherapy · 2013Review
- ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.Neuroendocrinology · 2012Article
- PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success.Pathology oncology research : POR · 2010Article
- Gastric acid hypersecretory states: recent insights and advances.Current gastroenterology reports · 2009Review
- Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.Gastroenterology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundZollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance.
aimsThe safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published. This study extends the initial observations to 3 years.
methodsThe primary efficacy end point for this report was the control of gastric acid secretion in the last hour before the next dose of oral pantoprazole (acid output of <10 mmol/h; <5 mmol/h in subjects with prior acid-reducing surgery). Dose titration was permitted to a maximum of 240 mg per 24 h.
resultsTwenty-four subjects completed the study. The acid output of 28 of 34 subjects was controlled at initial enrolment. The mean acid output rates were <10 mmol/h throughout the 36 months of treatment for 90-100% of the patients. The majority of the patients were controlled with b.d. doses of 40 or 80 mg pantoprazole at 36 months (acid output was controlled in 24 of 24 subjects). Pantoprazole was generally well tolerated with minimal adverse events reported.
conclusionsMaintenance oral pantoprazole therapy up to 3 years at dosages of 40-120 mg b.d. was effective and well tolerated in patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.